For research use only. Not for therapeutic Use.
CADD522(CAT: I019121) is a potent inhibitor targeting the RUNX2 transcription factor, primarily recognized for its critical role in oncology research. By disrupting RUNX2-mediated pathways, CADD522 offers a promising approach for studying tumor progression, metastasis, and cancer-related bone diseases. This compound is highly valuable for exploring novel therapeutic strategies and understanding transcriptional regulation in cancer biology. With its specificity and efficacy, CADD522 is an essential tool for advancing targeted drug discovery and preclinical cancer research, enabling breakthroughs in understanding and combating malignancies.
| Catalog Number | I019121 |
| CAS Number | 199735-88-1 |
| Molecular Formula | C₁₅H₁₃Cl₂NO₃ |
| Purity | ≥95% |
| Target | NF-κB |
| IUPAC Name | 3-[(3,4-dichlorophenyl)carbamoyl]bicyclo[2.2.1]hept-5-ene-2-carboxylic acid |
| InChI | InChI=1S/C15H13Cl2NO3/c16-10-4-3-9(6-11(10)17)18-14(19)12-7-1-2-8(5-7)13(12)15(20)21/h1-4,6-8,12-13H,5H2,(H,18,19)(H,20,21) |
| InChIKey | YSDNWNOGHQYWPK-UHFFFAOYSA-N |
| SMILES | C1C2C=CC1C(C2C(=O)NC3=CC(=C(C=C3)Cl)Cl)C(=O)O |
